The PI3K/AKT/mTOR pathway is among the most frequently dysregulated signaling axes in human cancers – and also one of the most difficult to suppress durably. Inhibiting PI3K alone triggers compensatory mTORC1 reactivation through AKT; blocking mTOR alone leaves upstream PI3K signaling intact. That feedback loop has driven interest in compounds that target both nodes simultaneously, and PF-05212384 – also known as gedatolisib or PKI-587 – is one of the most thoroughly characterized tools in that category.
Table of Contents
How the compound engages its targets
PF-05212384 is an ATP-competitive inhibitor that blocks all four class I PI3K isoforms alongside mTOR. Its IC50 values are 0.4 nM for p110α, 6 nM for p110β, 6 nM for p110γ, 8 nM for p110δ, and 1 nM for mTOR. That potency profile across the full isoform panel matters for research settings where isoform-selective tools would leave part of the signaling network untouched – and where the goal is understanding pathway-level dependence rather than isoform-specific contribution.
The compound’s selectivity has been evaluated against broader kinase panels, with no significant off-target effects observed on cardiac, CNS, or respiratory function in preclinical safety assessments. For experimental work requiring clean pathway attribution, that background is part of what makes the compound useful.
From cell assays to xenograft models
In vitro, PF-05212384 potently inhibited class I PI3Ks and mTOR, with growth inhibition observed across 50 diverse human tumor cell lines at IC50 values below 100 nM. In vivo activity was demonstrated across breast, colon, lung, and glioma xenograft models.
Subsequent work in ovarian cancer models added further context. Both gedatolisib and a related dual inhibitor produced tumor stasis during treatment across all tested patient-derived xenograft models, with an initial rapid reduction in tumor volume in several models during the first week. Biomarker data from those experiments – using phospho-S6 as a readout of mTOR activity – confirmed on-target engagement in responding models, which is the kind of mechanistic validation that makes a compound usable as a reference standard in new study designs.
What the clinical data adds to the preclinical picture
In a first-in-human phase I trial, the maximum tolerated dose for PF-05212384 administered intravenously once weekly was estimated at 154 mg. The study enrolled patients with advanced solid tumors and included pharmacodynamic profiling alongside safety endpoints – giving researchers a documented PK/PD relationship that spans from enzyme-level IC50 values through to measurable biological effects in humans. That continuity across experimental systems is what distinguishes a well-characterized probe from a compound that exists only in in vitro data.
For teams working on PI3K pathway biology, combination approaches, or resistance mechanisms in PI3K-driven tumors, PF-05212384 offers a defined inhibitor with a cross-validated profile and a documented clinical trajectory.
